- Management to host webcast on Saturday, Nov. 9, at 12:35 p.m. ET/ 6:35 p.m. CET
Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced that abstracts highlighting clinical and translational research data from the company’s pipeline of NKG2D-based candidates focused on the treatment of metastatic colorectal cancer (mCRC), including the allogeneic cell therapy CYAD-101, were published today ahead of the Society for Immunotherapy of Cancer’s 34thAnnual Meeting (SITC).
Filippo Petti, chief executive officer at Celyad, commented, “We are excited to provide additional updates at the upcoming SITC annual meeting from our current CAR-T program in metastatic colorectal cancer, including translational data from multiple approaches we have pursued with our NKG2D-based candidates for the treatment of the disease. Over the past few years, we have treated over thirty metastatic colorectal cancer patients within the program assessing various conditions. We continue to be encouraged by the results and prospects for the program and, in particular, from clinical data of our lead allogeneic candidate CYAD-101 where we have observed an absence of graft versus host disease and preliminary signals of clinical activity in a refractory, difficult to treat patient population.”
SITC Analyst/Investor Event and Webcast Information
Celyad will host an analyst/investor event on Saturday, Nov. 9, 2019, beginning at 12:35 p.m. ET / 6:35 p.m. CET to review both clinical and translational data that will be presented at the SITC 34th Annual Meeting. The event will be webcast live and can be accessed under Events & Webcasts in the Investors section of the Company’s website.
Poster Presentation Details
The following abstracts published today are now available on the SITC website, www.sitcancer.org/2019. Following presentation at the meeting, the posters will be available in the library section of Celyad’s website.Abstract P147: Effect of chemotherapy on cellular kinetics of NKG2D-based CAR T-cells in metastatic colorectal cancer patientsDate & Time: November 8, 7 a.m. – 8 p.m. ET Abstract P331: Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patientsDate & Time: November 8, 7 a.m. – 8 p.m. ET Abstract P330: Results from the completed dose-escalation of the alloSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patientsDate & Time: November 9, 7 a.m. – 8:30 p.m. ET
Background on SHRINK and alloSHRINK Trials
SHRINK is an open-label, dose-escalation Phase 1 trial assessing the safety and activity of CYAD-01 administered concurrently with FOLFOX chemotherapy in patients with metastatic colorectal cancer (mCRC). Patients are planned to receive consecutive cycles of FOLFOX (combination of 5-fluorouracil, leucovorin and oxaliplatin) chemotherapy every two weeks concurrently with multiple administrations of CYAD-01.
alloSHRINK is an open-label, dose-escalation Phase 1 trial assessing the safety and clinical activity of three consecutive administrations of CYAD-101 every 2 weeks administered concurrently with FOLFOX chemotherapy in patients with refractory mCRC.